Even before clinical symptoms of MS are evident, irreversible damage can begin. BETASERON is the only high-dose, high-frequency interferon beta FDA-approved for use at the first event.
This comprehensive overview includes compelling information about the clinical benefits of early treatment with BETASERON, the new BENEFIT Study 3-year data, and long-term measures of BETASERON efficacy.
A comprehensive guide to talking to patients, this piece explains MS, its effect on the body, and the variety of treatment options available. The Patient Counseling Tool also highlights the importance of early intervention, so patients understand the benefits of starting therapy early—and staying compliant over the long term.
BETASERON® (Interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Important Safety Information
The most commonly reported adverse reactions are lymphopenia, injection-site reaction, asthenia, flu-like symptom complex, headache and pain. Gradual dose titration and use of analgesics during treatment initiation may help reduce flu-like symptoms. BETASERON should be used with caution in patients with depression. Injection-site necrosis has been reported in 4% of patients in controlled trials. Patients should be advised of the importance of rotating injection sites. Female patients should be warned about the potential risk to pregnancy. Cases of anaphylaxis have been reported rarely. See "Warnings," "Precautions," and "Adverse Reactions" sections of full Prescribing Information.
